ImPassion130 Study Outcomes

ImPassion130 Study Outcomes

obr

2 months
29 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Sara Tolaney, MD, Associate Director, Susan F. Smith Center for Womens Cancers, Director Clinical Trials, Breast Oncology, Associate Professor of Medicine, Harvard Medical School shares the results of ImPassion130 study, a phase III adding atezolizumab to the 1st line chemotherapy with nab-paclitaxel in patients with PD-L1 positive metastatic triple-negative cancer (TNBC).
Up Next Autoplay